期刊文献+

肝恶性肿瘤患者肝动脉化疗栓塞术后继发感染病原菌及影响因素 被引量:2

Pathogen distribution and influencing factors for secondary infection after transcatheter arterial chemoembolization in patients with liver malignant tumor
原文传递
导出
摘要 目的 分析肝恶性肿瘤患者肝动脉化疗栓塞术(TACE)后继发感染的病原及影响因素。方法 选取2018年1月-2020年1月间南阳医学高等专科学校第一附属医院收治的43例TACE后继发感染患者作为感染组,并选取同期收治的43例TACE术后未感染者作为对照组。分析感染患者的病原菌和耐药性情况以及TACE术后感染发生的危险因素。结果 43例TACE术后继发感染者共培养分离病原菌48株,其中革兰阳性菌21株;革兰阴性菌27株;金黄色葡萄球菌对环丙沙星和左氧氟沙星耐药性较高,表皮葡萄球菌对左氧氟沙星和环丙沙星耐药性较高;大肠埃希菌、铜绿假单胞菌均对头孢唑林耐药性较高;两组年龄、手术时间、术前白蛋白水平、预防性使用抗生素时间、腹水情况差异有统计学意义(P<0.05);Logistic回归分析显示:年龄≥60岁、手术时间≥2 h、术前白蛋白<30.0 g/L、预防性使用抗生素时间<7 d、腹水均是影响TACE术后继发感染的独立危险因素(P<0.05)。结论 肝恶性肿瘤患者TACE术后继发感染的影响因素较多,规范预防性抗菌药物使用、调整术前患者身体状况对降低感染风险有利。 OBJECTIVE To analyze the etiology and influencing factors for secondary infection after hepatic arterial chemoembolization(TACE) in patients with hepatic malignant tumor. METHODS The clinical data of 43 patients with secondary infection after TACE admitted to the First Affiliated Hospital of Nanyang Medical College from Jan 2018 to Jan 2020 were retrospectively analyzed and divided into the infection group;43 patients without infection after TACE during the same period were in the control group. The pathogenic bacteria distribution and drug-resistance of the strains in the infected patients were analyzed, and the risk factors for postoperative TACE infection were analyzed. RESULTS 48 strains of pathogenic bacteria were isolated from 43 patients with secondary infection after TACE, including 21 strains of gram-positive bacteria and 27 strains of Gram-negative bacteria. Staphylococcus aureus had the highest drug-resistance to ciprofloxacin and cefazolin;Staphylococcus epidermidis had the highest drug resistance to levofloxacin and ciprofloxacin;Escherichia coli and Pseudomonas aeruginosa were highly resistant to cefazolin. There were significant differences in age, operation time, preoperative albumin level, prophylactic antibiotic use time and ascites status between the two groups(P<0.05). Multivariate Logistic regression analysis showed that age, operation time, preoperative albumin, prophylactic antibiotic use time and ascites were all independent risk factors for secondary infection after TACE(P<0.05). CONCLUSION There are many influencing factors for secondary infection after TACE in patients with hepatic malignant tumor. Standardization of prophylactic antibiotics usage and the improvement of patients′ physical condition before surgery is benefit to reduce the risk of infection.
作者 赵琳 李华 ZHAO Lin;LI Hua(The First Affiliated Hospital of Nanyang Medical College,Nanyang,Henan 473006,China;不详)
出处 《中华医院感染学杂志》 CAS CSCD 北大核心 2022年第7期1046-1049,共4页 Chinese Journal of Nosocomiology
基金 河南省医学科技攻关计划基金资助项目(LHGJ20190421)。
关键词 肝癌 肝动脉化疗栓塞术 感染 病原菌 耐药性 影响因素 Liver cancer Hepatic arterial chemoembolization Infection Pathogenic bacteria Drug resistance Influencing factors
  • 相关文献

参考文献12

二级参考文献90

  • 1曹洪友,赵新建.肝癌介入化疗栓塞术后并发症相关因素分析[J].医学信息(医学与计算机应用),2014,0(5):27-28. 被引量:3
  • 2Agrawal S, Belghiti J. Oncologic resection for malignant tumors of the liver[J]. Ann Surg, 2011,253(4) :656-665.
  • 3Okabe H, Beppu T, Ishiko T, et al. Preoperative portal vein embolization (PVE) for patients with hepatocellular carcinoma can improve resectability and may improve disease-free survival [J]. J Surg Oncol, 2011,104(6):641-646.
  • 4Guiu B, Bize P, Demartines N, et al. Simultaneous biliary drainage and portal vein embolization before extended hepatectomy for hilar cholangiocarcinoma : preliminary experience[J]. Cardiovasc Intervent Radiol, 2014, a7 (a) : 698-704.
  • 5Huang SY, Aloia TA, Shindoh J,et al. Efficacy and safety of portal vein embolization for two-stage hepatectomy in patients with colorectal liver metastasis[J]. J Vasc Interv Radiol, 2014,25(4) :608-617.
  • 6Truty MJ, Vauthey JN. Uses and limitations of portal vein embolization for improving perioperative outcomes in hepatocellular carcinoma[J]. Semin Oncol, 2010, 37 (2) :102-109.
  • 7Song P. Standardizing management of hepatocellular carcinoma in China: devising evidence-based clinical practice guidelines [J]. Biosei Trends, 2013,7(5) :250-252.
  • 8Chen XP, Huang ZY. Surgical treatment of hepatocellular carcinoma in China: surgical techniques, indications, and outcomes[J]. Langenbecks Arch Surg, 2005, 390 (3):259-265.
  • 9van Gulik TM, van den Esschert JW, de Graaf W, et al. Controversies in the use of portal vein embolization[J]. Dig Surg, 2008, 25(6):436-444.
  • 10Fan J, Tang ZY, Yu YQ, et al. Improved survival with resection after transcatheter arterial ehemoembolization (TACE) for unresectable hepatoeellular careinoma[J]. Dig Surg, 1998,15(6) :674-678.

共引文献7005

同被引文献28

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部